

Conference Registration

Paris Anti-Inflammatory Drugs - 6,7 october 2005

To register, please fill in this form and return it by regular mail to the Paris Anti-Inflammatory Drugs 2005 secretariat :
 Paris Anti-Inflammatory Drugs 2005 - Takayama - 15 Rue de la Paix - 75002 Paris - France.
 Phone :+33 1 55 04 77 55 / Fax :+33 1 55 04 77 57
 anti-inflammatory2005@wanadoo.fr - http://www.isanh.com

Mr Mrs Pr Dr First name : Last name :
 Company : Organisation : Department :
 Address :
 Postal code : City : Country :
 Telephone :
 Fax :
 Email :

Paris Anti-Inflammatory Drugs 2005 registration fees*	Before August 15th	After August 15th
<input type="checkbox"/> Student** :	295 € TTC	395 € TTC
<input type="checkbox"/> Academic :	495 € TTC	595 € TTC
<input type="checkbox"/> Industrial :	895€ TTC	995 € TTC
<input type="checkbox"/> I wish to purchase the Abstract Book :95€		
<input type="checkbox"/> I wish to attend the Gala Dinner :	65€ TTC	65€ TTC
Total amount due _____€		

*Registration fees include lunches, coffee/tea breaks and the abstract book

**Student : please provide a copy of your student card

Payment (registration forms must be accompanied by full payment) :

Please enclose a copy of the bank transfer with your registration form. Bank fees are at your charge.

My payment has been effected by bank transfer to National Bank of Paris (BNP),59 Avenue d'Italie 75013 Paris.***

Bank Code :30004

Agency :00895

Account number :00010008521 Key :26

IBAN :FR 76 3000 4008 9500 0100 0852 126

CODE SWIFT : BNPA FR PPP GB

I have enclosed a certified cheque made payable to Takayama with this form

Charge the total amount due to this credit card :AMERICAN EXPRESS – EURO/MASTER/ACCESS – VISA (registration fee will be deducted from your credit card by Takayama prior to the congress)

Name card holder : _____

Credit card number : _____ Expiry date : _____

Signature _____ Place : _____ Date : _____

***Fees at your charge

Upon receiving your registration fee per credit card, certified cheque or bank transfer, a confirmation will be send to you. Please make a copy of this form for your own file.

Cancellation policy :

Refund of the registration fees must be applied for in writing to the the Paris Anti-Inflammatory Drugs 2005 secretariat.

Cancellations of registration received one month before the conference date will be refunded minus 350 Euros administrative charges.

For cancellations received after this date, no refund can be made. All refunds are settled after the conference.



Latest Advances on Anti-Inflammatory Molecules : Innovations and Perspectives



Pasteur Institute, Paris - France
October 6-7, 2005

> Scientific Committee and Speakers <

Pr Pierre Miossec (Lyon, France),

Dr Michel Chignard (Paris, France),

Pr John Wallace (Calgary, Canada),

Dr Marvin Edeas (Paris, France),

Pr Jari Koistinaho (Kuopio, Finland),

Pr Roderick Flower (London, UK),

Dr Pascal Eschwege (Le Kremlin-Bicêtre, France),

Pr Thomas Simmet (Ulm, Germany),

Dr Fabrice Thoulon (Magne Vernois, France),

Pr Bernard Combe (Montpellier, France),

Pr Jean Pierre Pujol (Caen, France),

Dr Gerd Bouma (Amsterdam, The Netherlands),

Pr Mustapha Rouis (Lille, France),

Pr Christopher Griffiths (Manchester, UK),

Pr Neil Barnes (London, UK),


Mrs Katia Musitu (London, UK),

Dr Alain Chariot (Liège, Belgium),

Dr Jacques Morel (Montpellier, France),

Scientific Information :

Société Française des Antioxydants (SFA) - anti-inflammatory2005@wanadoo.fr - www.isanh.com



Dear colleagues,

On behalf of the Organizing Committee, we are happy to invite you to attend the 1st International Conference on The Latest Advances On Anti-Inflammatory Molecules : Innovations And Perspectives (Paris Anti-Inflammatory Drugs 2005) which will take place at the Pasteur Institute in Paris-France on October 6-7 2005.

"Paris Anti-Inflammatory Drugs 2005" aims to bring together world specialists in order to explore the latest scientific advances on anti-inflammatory drugs. It proposes to launch the discussion on the latest innovations, new applications and new pathways which will allow the development of more efficient and safer anti-inflammatory drugs in the future.

The themes of "Paris Anti-Inflammatory Drugs 2005" are : Economic impact, Synthetic Anti-Inflammatory Drugs, Biological Anti-Inflammatory Drugs, Natural Anti-Inflammatory Ingredients, Side Effects, Models to test Anti-Inflammatory Efficacy, Antioxidants and Inflammation, Rheumatoid Arthritis, Inflammatory Bowel Diseases, Airway Inflammation, Cardio-Vascular Diseases, Inflammation and Cancer, Neurodegenerative Diseases, Dermatological Diseases, Veterinary Medicine, Latest Pharmaceutical Innovations.

This conference is open to researchers and academic professors, R&D departments, clinicians, pharmaceutical companies, food supplement companies, cosmetics companies, veterinary medicine companies, marketing departments, investors, start ups and actors of the economic environment.

We would like to express our deep gratitude to ISANH and all companies and journals who supported the organization of "Paris Anti-Inflammatory Drugs 2005".

Dr Marvin Edeas, Chairman of the Organizing Committee
President of the French Society for Antioxidants

8:30 > Registration and Welcome Address

9:00 > Economic Impact of Anti-Inflammatory Drugs

- What market share do anti-inflammatory drugs have in France, in Europe and world wide ?
- What are the most used anti-inflammatory drugs and for which pathologies ?
- What impacts did the problems surrounding the two anti-inflammatory drugs of the coxibs family in 2004 have ?
- What are the latest trends in the anti-inflammatory drug market ?
Mrs Katia Mustu, IMS Health, London, UK

SESSION 1 : Anti-Inflammatory Drugs : Molecules and Mechanisms of Action

Chairmen :
Pr Roderick Flower, Pr John Wallace and Dr Marvin Edeas

9:45 > Inflammation and Anti-Inflammatory Drugs : General Presentation

- History : from the Willow tree bark to present day
- The different classes of anti-inflammatory drugs :
 - The traditional anti-inflammatory drugs: corticosteroids, non steroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase 2 (COX2) inhibitors...
 - The emerging anti-inflammatory drugs : COX/lipoxygenase inhibitors, nitric oxide-releasing non steroidal anti-inflammatory drugs, antibodies directed against specific molecules involved in the inflammatory reaction...
- What impact have anti-inflammatory drugs had on public health throughout the years ?
Pr Roderick Flower, William Harvey Research Institute, London, UK

> 10:30 Break <

11:00 > Mechanisms of Action of the Synthetic Anti-Inflammatory Drugs

- Inhibition of eicosanoids synthesis: inhibition of COX1 and COX2, inhibition of phospholipase A2, inhibition of lipoxins synthesis (LXs)...
- COX-independent mechanisms: activation or inhibition of peroxisome proliferator-activated receptors (PPARs), inhibition of NF kappa B, inhibition of the BCL-2 gene expression...
Dr Pascal Eschwege, Department of Urology Hôpital Bicêtre, Le Kremlin Bicêtre, France

11:45 > Mechanisms of Action of the Biological Anti-Inflammatory Drugs

- Antibodies against cytokines or other actors involved in inflammation: new inflammatory cytokines inhibitors and other potential targets (IL-1 trap, anti-IL-17...)
- Sens and antisens oligonucleotides, interference RNA (RNAi)
Pr Pierre Miossec, Université de Lyon, Lyon, France

> 12:30 Lunch <

SESSION 2 : Anti-Inflammatory Drugs and Main Inflammatory Diseases

Chairmen :
Pr Pierre Miossec, Pr Gerit Bouma, Dr Michel Chignard and Dr Pascal Eschwege

14:00 > Latest Advances in the Anti-Inflammatory Treatment of Rheumatoid Arthritis

- Presentation and pathogenesis of RA
- What are the current anti-inflammatory therapies to treat this pathology ? What are the clinical results, the problems and side effects of these therapies ?
 - Non steroidal anti-inflammatory drugs and COX-2 inhibitors
 - Classical Disease modifying antirheumatic drugs (DMARDs)
- Heterogeneity in the response to cytokine inhibitors and pharmacogenomic
- What are the new therapies in development to treat RA ?
 - inhibition of co-stimulatory molecules (CTLA-1g)
 - anti-CD20 monoclonal antibodies
 - anti-IL-6 receptor (MRA)
 - matrix metallo-proteinases (MMPs) inhibitors
 - interleukine 1 converting enzyme (ICE) inhibitors
 - Kinases inhibitors : p38 MAPK, c-jun N-terminal kinase
 - new inflammatory cytokines inhibitors
Pr Jacques Morel, Department of Immunology-Rheumatology, Lapeyronnie Hospital, Montpellier, France

14:45 > Latest Advances in the Anti-Inflammatory Treatment of Inflammatory Bowel Disease

- Presentation and pathogenesis of inflammatory bowel diseases : Crohn's disease, ulcerative colitis...
- What are the current anti-inflammatory therapies to treat these pathologies ?
 - anti-TNF alpha therapies
 - anti-integrines therapies
- What are the new therapies in development to treat these pathologies ?
 - Thérapies based on apoptosis induction : anti-IL-12 antibodies...
 - Release of IL-10 or TGF beta on the inflammatory site
 - Nucleotide-binding oligomerization domain 2 (NOD2) : a new target ?
Dr Gerd Bouma, Department of Immunogenetics, Vrije Universiteit Medical Center, Amsterdam, The Netherlands

> 15:30 Break <

16:00 > Latest Advances in the Anti-Inflammatory Treatment of Airway Inflammation

- Presentation and pathogenesis of inflammatory airway inflammations: asthma, chronic obstructive pulmonary disease (COPD)...
- What are the current anti-inflammatory therapies to treat these pathologies ?
 - Therapies based on glucocorticoides
 - Anti-leukotrienes and inhibitors of 5-lipoxygenase (5-LO)
 - Anti-cytokines and anti-chemokines therapies
- What are the perspectives to treat airway inflammation ?
 - New generation of glucocorticoides
 - Inhibitors and activators of PPARs
 - Cellular adhesion molecule inhibition
 - Antisens therapies : respirable antisens oligonucleotides
Pr Neil Barnes, The London Chest Hospital, London, UK

16:45 > Latest Advances in the Anti-Inflammatory Treatment of Cardio-Vascular Disease

- Presentation and pathogenesis of inflammatory cardiovascular diseases: atherosclerosis, coronary artery disease...
- What are the current anti-inflammatory therapies to treat these pathologies ?
- What are the new pathways that could be used to develop new treatments for these pathologies ?
 - Inhibitors and activators of PPARs
 - Liver X receptors (LXRs) agonists
 - MMPs inhibitors
 - Cellular adhesion molecule inhibition
Pr Mustapha Routs, Institut Pasteur de Lille, Lille, France

> 17:30 End of the Day <

Friday 7th October

9:00 > Two Anti-Inflammatory Drugs Deemed Dangerous for Patients : Polemic, Strategies and Consequences

- Background information
- What criteria were used to evaluate the dangerous nature of VIOXX and Celebrex for patients ?
- Why was the problem not detected before the product launch ?
- Figures for the two drugs : market share before the announcement and losses incurred by the laboratories after the affair
- The benefit/risk ratio of a drug
- How to produce safe drugs and remain competitive on the market ?
(Proposed to Pr Jean Hugues Trouvin, Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS), Paris, France)

9:45 > Side Effects of Anti-Inflammatory Drugs

- Effects on the gastro-intestinal tract
- Effects on the liver
- Side effects of COX2 inhibitors on the cardio-vascular system
- What are the various strategies to decrease the side effects of anti-inflammatory drugs ?
Pr John Wallace, University of Calgary, Calgary, Alberta, Canada

> 10:30 Break <

11:00 > How can We Evaluate the Efficiency of an Anti-Inflammatory Drug ?

- In vitro tests, in vivo tests : What models currently exist ?
- What are their limits and weaknesses ?
- Which models are the most efficient at the moment ?
- Are new models being developed ?
Pr Jean Pierre Pujol, University of Caen, France

SESSION 3 : Innovations and Perspectives in Anti-Inflammatory Therapies

Chairmen :
Pr Jari Koistinaho, Pr Christopher Griffiths and Pr Thomas Simmet

11:45 > Oxidative Stress and Inflammation : What Roles for Antioxidants as Anti-Inflammatory Drugs ?

- What are the mechanisms of action of antioxidants : inhibition of NF kappa B, decrease of inflammatory cytokine expression, re-establishment of the cellular redox state ?
- Potential role of antioxidants as anti-inflammatory drugs : example of the superoxide dismutase (SOD) and polyphenols
Dr Marvin Edeas, President of the French Society for Antioxidants, Paris, France

12:05 > When Inflammation Leads to Cancer

- What are the correlations between inflammation and cancer ?
- What role do the IKK NF kappa B system and toll-like receptors (TLRs) play ?
- What new treatment perspectives can arise from the involvement of these molecules ?
Dr Alain Chariot, University of Liege, Liege, Belgium

> 12:30 Lunch <

14:00 > Anti-Inflammatory Drugs and Neurodegenerative Diseases

- Presentation and pathogenesis of inflammatory neurodegenerative diseases : Alzheimer's disease, multiple sclerosis...
- What therapies can be used in these pathologies ?
 - Anti-integrins therapy : natalizumab
 - NSAIDs
Pr Jari Koistinaho, AI Vri tanen Institute for Molecular Sciences, University of Kuopio, Kuopio, Finland

14:20 > Anti-Inflammatory Drugs and Dermatological Diseases

- Presentation and pathogenesis of inflammatory dermatological diseases : psoriasis, psoriatic arthritis...
- What therapies can be used in these pathologies ?
- Anti-cytokine therapies : IL-1 and IL-17, TNF alpha, IL-23, IFN gamma...
Pr Christopher Griffiths, University of Manchester, Manchester, UK

14:40 > Anti-Inflammatory Drugs and Veterinary Medicine

- The Veterinary Market
- Main pathologies requiring the use of AI drugs in domestic animals and differences with human medicine : in dogs, in cats, in horses and in cattle
- Products used in the veterinary field (with or without veterinary MA)
- Regulatory issues
Dr Fabrice Thoulon, Vétérinaire, Magny Vernois, France

15:00 > Natural Anti-Inflammatory Drugs : Recent Developments

- What are the most promising products to cure inflammatory diseases ? Clinical evidences
- What are the mechanisms of action of natural anti-inflammatory drugs ? Example of the triterpenoids
- What are the perspectives for these molecules ?
Pr Thomas Simmet, University of Ulm, Ulm, Germany

> 15h40 Break <

16:10 > Role and Efficiency of Natural Anti-Inflammatory Ingredients

- Curcuma longa, Devil's claw root, Cat's claw...
- Green tea extracts
- Phenolic acids : ferulic acid, caffeic acid, gallic acid
- Fatty acids : omega 3, omega 6
Dr Eric Martinez, the French Society for Antioxidants, Paris, France

SESSION 4 : Latest Pharmaceutical Innovations in the Anti-Inflammatory Field

16:40 > What Are the Latest Innovations in the Anti-Inflammatory Drug Field : Presentations by Pharmaceutical Laboratories and Start-Ups (10 minutes to convince)

If you want to present your innovation, please contact us.

Already selected :

Systemic low dose antisense delivery and anti-inflammatory effect using Smarticles® vectors
Steffen Panzner, Novosom AG

Signaling Pathways and the Future of Anti-inflammatory Drugs
Alan Lewis, Celgene

Round Table Discussion

17:30 > Anti-Inflammatories of the Future : Myth or Reality ? (In the Presence of the Scientific Committee)

- What characteristics must the ideal anti-inflammatory drug possess ?
- What is the most promising pathway to inhibit inflammation ?
- What other new pathologies could be treated by anti-inflammatory drugs ?

Pr Pierre Miossec, Dr Michel Chignard, Pr John Wallace, Dr Marvin Edeas, Pr Jari Koistinaho, Pr Rod Flower, Dr Pascal Eschwege, Pr Thomas Simmet, Dr Fabrice Thoulon, Pr Bernard Combe, Dr Jacques Morel, Pr Jean Pierre Pujol, Dr Gerd Bouma, Pr Mustapha Routs, Pr Christopher Griffiths, Pr Neil Barnes, Dr Alain Chariot.

Anti-Inflammatory Drugs 2005 Innovation Award

The scientific committee will name the most innovative project upon oral or poster presentation

Useful information :

- Dead line for the abstracts submission : September 2, 2005
- Notification on acceptance of abstracts : September 30, 2005
- Early registration fee payment : August 15, 2005

• Abstracts can be sent as a word file to the following address :
anti-inflammatory2005@wanadoo.fr

- Posters will be selected by the scientific committee upon abstract submission

For more information :
French Society for Antioxidants (SFA)
15 rue de la Paix - 75002 Paris
Phone : 00 33 1 55 04 77 55 - Fax : 00 33 1 55 04 77 57
www.isanh.com